Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapRI: Adjuvant interferon alpha-2b and 5-FU with or without radiation and cisplatin in resected pancreatic adenocarcinoma
2008-000121-19Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Jun 2008
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of interferon alfa-2b, fluorouracil and cisplatin in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Heidelberg University. Primary endpoint: Event-free survival. Started Jun 2008; status: terminated.
02
Drugs
interferon alfa-2bfluorouracilcisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2008-000121-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000121-19.